Enactment of FDA Reform Act Improves Drug Safety - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Enactment of FDA Reform Act Improves Drug Safety
New law provides FDA with the resources it needs to safeguard drug supply chain.

Pharmaceutical Technology
Volume 36, Issue 8, pp. 113-114

Industry and FDA collaborate

Among the most significant but least-known developments contributing to this legislative success is the fact that, at a time when company budgets are tight and economic uncertainty runs high, generic-drug producers voluntarily agreed to pay these fees to avoid another heparin-like tragedy. Improving the safety of drugs throughout the supply chain will come at great expense and will only succeed through the diligence of all stakeholders. FDA must be attentive with its drug approval and inspection procedures, and drug producers must remain committed to manufacturing drug ingredients governed by cGMPs. The pharmaceutical industry becomes more global each day, and it becomes increasingly clear that all manufacturers must work to implement quality programs.

As the law is implemented in stages over the next few years, the hope is that the industry will see results from these major steps taken to safeguard the drug supply. The ongoing dialogue between drug manufacturers and FDA has led to a path forward that can hopefully ease the minds of consumers. However, there is more work to be done. Currently, foreign over-the-counter (OTC) drug manufacturing is not being inspected, nor is their inspection included in the passage of the FDA Reform Act. Hopefully, a risk-based inspection approach will be applied to OTC products as well in the future.

John DiLoreto is executive director of the Bulk Pharmaceuticals Task Force, an affiliate organization of the Society of Chemical Manufacturers and Affiliates (SOCMA).


1. B. Nychis, Import of Human Drugs and Human Drug Components, CDER Office of Compliance, Office of Drug Security, Integrity & Recalls, Division of Import Operations & Recalls, Import Operations Branch (IOB), Presentation (June 2011).

2. FDA, Pathway to Global Product Safety and Quality, A Special Report, Revised (July 2011).

3. FDA, Drug Safety: FDA Has Conducted More Foreign Inspections and Begun to Improve Its Information on Foreign Establishments, but More Progress Is Needed, United States Government Accountability Office, Report to the Committee on Oversight and Government Reform, House of Representatives, GAO-10-961 (September 2010).

4. FDA, Fact Sheet: New User Fees for Generic Drugs Will Enhance Americans' Access to Less Expensive Drugs and Generate Major Cost Savings, GDUFA Performance Goals and Efficiency Improvements, Inspection Metrics (July 9, 2012).


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here